1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys Kodiak Sciences Inc, Adaptive Biotechnologies Corp, Ra Pharmaceuticals Inc, Sells Clementia Pharmaceuticals Inc, Array BioPharma Inc, Axsome Therapeutics Inc

New York, NY, based Investment company Baker Bros. Advisors Lp (Current Portfolio) buys Kodiak Sciences Inc, Adaptive Biotechnologies Corp, Ra Pharmaceuticals Inc, Neurocrine Biosciences Inc, Acorda Therapeutics Inc, sells Clementia Pharmaceuticals Inc, Array BioPharma Inc, Axsome Therapeutics Inc, Macrogenics Inc, InflaRx NV during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2019Q2, Baker Bros. Advisors Lp owns 96 stocks with a total value of $14.6 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seattle Genetics Inc (SGEN) - 50,057,277 shares, 23.78% of the total portfolio. Shares reduced by 1.94%
  2. Incyte Corp (INCY) - 31,976,193 shares, 18.64% of the total portfolio. Shares reduced by 6.7%
  3. BeiGene Ltd (BGNE) - 11,777,285 shares, 10.02% of the total portfolio. Shares reduced by 1.53%
  4. Alexion Pharmaceuticals Inc (ALXN) - 8,258,068 shares, 7.42% of the total portfolio. Shares reduced by 3.51%
  5. ACADIA Pharmaceuticals Inc (ACAD) - 39,292,086 shares, 7.21% of the total portfolio. Shares reduced by 1.06%
New Purchase: Kodiak Sciences Inc (KOD)

Baker Bros. Advisors Lp initiated holding in Kodiak Sciences Inc. The purchase prices were between $6.2 and $12, with an estimated average price of $8.88. The stock is now traded at around $11.60. The impact to a portfolio due to this purchase was 0.73%. The holding were 9,145,115 shares as of .

New Purchase: Adaptive Biotechnologies Corp (ADPT)

Baker Bros. Advisors Lp initiated holding in Adaptive Biotechnologies Corp. The purchase prices were between $40.3 and $48.3, with an estimated average price of $44.3. The stock is now traded at around $45.04. The impact to a portfolio due to this purchase was 0.39%. The holding were 1,165,411 shares as of .

New Purchase: Orchard Therapeutics PLC (ORTX)

Baker Bros. Advisors Lp initiated holding in Orchard Therapeutics PLC. The purchase prices were between $13.2 and $20.63, with an estimated average price of $17.58. The stock is now traded at around $14.09. The impact to a portfolio due to this purchase was 0.04%. The holding were 405,702 shares as of .

New Purchase: XBiotech Inc (XBIT)

Baker Bros. Advisors Lp initiated holding in XBiotech Inc. The purchase prices were between $6.99 and $11.27, with an estimated average price of $8.7. The stock is now traded at around $8.09. The impact to a portfolio due to this purchase was 0.02%. The holding were 380,442 shares as of .

New Purchase: NextCure Inc (NXTC)

Baker Bros. Advisors Lp initiated holding in NextCure Inc. The purchase prices were between $14.16 and $20.64, with an estimated average price of $17.39. The stock is now traded at around $25.92. The impact to a portfolio due to this purchase was 0.02%. The holding were 150,000 shares as of .

New Purchase: Cyclerion Therapeutics Inc (CYCN)

Baker Bros. Advisors Lp initiated holding in Cyclerion Therapeutics Inc. The purchase prices were between $9.6 and $22.85, with an estimated average price of $14.45. The stock is now traded at around $8.85. The impact to a portfolio due to this purchase was 0.02%. The holding were 202,581 shares as of .

Added: Ra Pharmaceuticals Inc (RARX)

Baker Bros. Advisors Lp added to a holding in Ra Pharmaceuticals Inc by 118.89%. The purchase prices were between $19.88 and $30.07, with an estimated average price of $22.88. The stock is now traded at around $29.24. The impact to a portfolio due to this purchase was 0.2%. The holding were 1,801,695 shares as of .

Added: Neurocrine Biosciences Inc (NBIX)

Baker Bros. Advisors Lp added to a holding in Neurocrine Biosciences Inc by 28.82%. The purchase prices were between $72.24 and $91.27, with an estimated average price of $82.02. The stock is now traded at around $97.03. The impact to a portfolio due to this purchase was 0.18%. The holding were 1,415,283 shares as of .

Added: Acorda Therapeutics Inc (ACOR)

Baker Bros. Advisors Lp added to a holding in Acorda Therapeutics Inc by 588.45%. The purchase prices were between $6.93 and $13.41, with an estimated average price of $10.25. The stock is now traded at around $3.22. The impact to a portfolio due to this purchase was 0.09%. The holding were 2,011,189 shares as of .

Added: Krystal Biotech Inc (KRYS)

Baker Bros. Advisors Lp added to a holding in Krystal Biotech Inc by 31.86%. The purchase prices were between $27.2 and $41.2, with an estimated average price of $32.66. The stock is now traded at around $44.01. The impact to a portfolio due to this purchase was 0.07%. The holding were 1,034,674 shares as of .

Added: La Jolla Pharmaceutical Co (LJPC)

Baker Bros. Advisors Lp added to a holding in La Jolla Pharmaceutical Co by 208.61%. The purchase prices were between $5.32 and $12.86, with an estimated average price of $7.5. The stock is now traded at around $9.96. The impact to a portfolio due to this purchase was 0.07%. The holding were 1,559,231 shares as of .

Added: Assembly Biosciences Inc (ASMB)

Baker Bros. Advisors Lp added to a holding in Assembly Biosciences Inc by 440.59%. The purchase prices were between $12.9 and $20.8, with an estimated average price of $15.85. The stock is now traded at around $12.47. The impact to a portfolio due to this purchase was 0.06%. The holding were 803,246 shares as of .

Sold Out: Clementia Pharmaceuticals Inc (CMTA)

Baker Bros. Advisors Lp sold out a holding in Clementia Pharmaceuticals Inc. The sale prices were between $25.95 and $26.49, with an estimated average price of $26.23.

Sold Out: InflaRx NV (IFRX)

Baker Bros. Advisors Lp sold out a holding in InflaRx NV. The sale prices were between $3.06 and $51.61, with an estimated average price of $31.98.

Sold Out: Macrogenics Inc (MGNX)

Baker Bros. Advisors Lp sold out a holding in Macrogenics Inc. The sale prices were between $14.51 and $19.71, with an estimated average price of $17.19.

Sold Out: ContraFect Corp (CFRX)

Baker Bros. Advisors Lp sold out a holding in ContraFect Corp. The sale prices were between $0.39 and $0.65, with an estimated average price of $0.49.



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
/* */